Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04818970 · ClinicalTrials.gov registry record · NA
Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients
A NA study of COVID-19 and Corona Virus Infection, sponsored by Cytokind.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04818970: Completed NA study of COVID-19 and Corona Virus Infection, sponsored by Cytokind.
NCT04818970 is a NA study of COVID-19 and Corona Virus Infection that has completed, run by Cytokind. The registered enrollment target is 30 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04818970, a NA study of COVID-19 and Corona Virus Infection, has completed, sponsored by Cytokind.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study to evaluate the translational application of the safe and effective treatment of Narrow-Band Ultraviolet light B-band (NB-UVB) to high-risk COVID-19 patients in an effort to improve their immune and hemostatic imbalance to increase survival and improve outcomes.
Primary Outcome
% Patient Mortality
Conditions Studied
Interventions
- DEVICE Narrow Band ultraviolet B-Band Light
- DEVICE non Narrow Band ultraviolet B-Band Light
Study Locations (1)
Louisiana
- West Jefferson Medical Center and LSUHSC-NO - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-05-21 |
| Est. Completion | 2021-12-01 |
| Phase | NA |
What the finished NCT04818970 record still lists
NCT04818970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Narrow Band ultraviolet B-Band Light is the first listed.
NCT04818970 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT04818970 about?
NCT04818970 is a clinical study titled "Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients". The purpose of this study to evaluate the translational application of the safe and effective treatment of Narrow-Band Ultraviolet light B-band (NB-UVB) to high-risk COVID-19 patients in an effort to improve their immune and hemostatic imbalance to increase survival and improve outcomes.
What is the current status of trial NCT04818970?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-05-21. Estimated completion is 2021-12-01.
What conditions does trial NCT04818970 study?
This clinical trial studies the following conditions: COVID-19, Corona Virus Infection, Autoimmune Diseases, Coagulation Disorder, Blood.
What interventions are being tested in trial NCT04818970?
The interventions under investigation include: Narrow Band ultraviolet B-Band Light (DEVICE), non Narrow Band ultraviolet B-Band Light (DEVICE).
Who is sponsoring clinical trial NCT04818970?
This trial is sponsored by Cytokind, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04818970 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04818970's enrollment target sits among peer trials
30 265th of 298 higher than 28 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Music Mindfulness Study 2a.
RECRUITING · NA
-
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
RECRUITING · NA
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Evaluating the Impact of Social Music
RECRUITING · NA
-
The SINCERE Intervention to Address COVID-19 Health Disparities
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI